Abstract
Purpose
Extramedullary leukaemic disease (EMD, synonym chloroma) is a rare solid manifestation of myeloid leukaemia for which the value of radiotherapy (RT) as a treatment strategy remains controversial. The aim of this study is to analyse the effectiveness of various RT doses for EMD in the modern treatment era.
Materials and methods
Between January 2000 and June 2016, 20 patients with total of 45 lesions underwent RT for EMD at our institution.
Results
With a median radiation dose of 26 Gy (range 4–42 Gy), local remission could be achieved in 91% of patients (complete remission rate: 71%). The median duration of local control (DOLC) was 17 months (95% confidence interval [CI] 0.5–33) and the median overall survival (OS) after chloroma onset was 24 months (95% CI 11–38). No noticeable difference between high- and low-dose regimens has been observed (74% versus 68%; P = 0.5). In the multivariate analysis, only Eastern Cooperative Oncology Group (ECOG) score and bone marrow state during RT have proven to be determinant for durable local control and OS.
Conclusions
Low-dose RT (≤26 Gy) achieves good local control compared to high-dose regimes. Bone marrow state during RT and ECOG score during RT may play a crucial role, influencing both DOLC and OS.
Zusammenfassung
Zielsetzung
Extramedulläre leukämische Infiltrate (EMD) sind seltene Manifestationen myeloischer Leukämien, in deren Behandlungskonzepten der Stellenwert der Radiotherapie (RT) unklar ist. Das Ziel der vorgelegten Studie ist es, die Wirksamkeit verschiedener Strahlentherapiedosen für EMD in der modernen Behandlungsära zu untersuchen.
Material und Methoden
Zwischen Januar 2000 und Juni 2016 durchliefen 20 Patienten mit insgesamt 45 Läsionen eine RT für EMD in unserer Klinik.
Ergebnisse
Mit einer mittleren RT-Dosis von 26 Gy (Spanne 4–42 Gy) konnte eine lokale Remission bei 91 % der Patienten erzielt werden (komplette Remissionsrate, CRR: 71 %). Die mittlere Dauer der Lokalkontrolle (DOLC) betrug 17 Monate (95 %-KI 0,5–33) und das mediane Gesamtüberleben (OS) nach Chloromadiagnose war 24 Monate (95 %-KI 11–38). Es fand sich kein wesentlicher Unterschied zwischen Niedrig- und Hochdosis-RT (74 % versus 68 %; P = 0,5). Läsionen mit einer günstigen Prognose nach zytogenetischen und molekulargenetischen Faktoren sowie Läsionen, die mit einer modernen Strahlentherapietechnik wie intensitätsmodulierter Radiotherapie (IMRT) behandelt wurden, erreichten eine CRR von 100 % (P = 0,05 bzw. P = 0,008). In der multivariaten Analyse zeigten sich der ECOG-Score (Eastern Cooperative Oncology Group) und eine Remission im Knochenmark als entscheidend für die lokale Kontrolle, während der ECOG-Score, die Bestrahlungstechnik und das Ansprechen auf die RT das OS beeinflussten.
Schlussfolgerungen
Niedrigdosis-RT (≤26 Gy) erzielt eine ebenso gute lokale Kontrolle wie Behandlungskonzepte mit höherer Dosis. Der ECOG-Score vor der RT scheint eine zentrale Rolle für OS und DOLC zu spielen.
Similar content being viewed by others
References
Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951. https://doi.org/10.1182/blood-2009-03-209262
Agis H, Weltermann A, Fonatsch C et al (2002) A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol 81:90–95. https://doi.org/10.1007/s00277-001-0412-9
Ganzel C, Manola J, Douer D et al (2016) Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. J Clin Oncol 34:3544–3553. https://doi.org/10.1200/JCO.2016.67.5892
Movassaghian M, Brunner AM, Blonquist TM et al (2015) Presentation and outcomes among patients with isolated myeloid sarcoma: a surveillance, epidemiology, and end results database analysis. Leuk Lymphoma 56:1698–1703. https://doi.org/10.3109/10428194.2014.963080
King A (1853) A case of chloroma. Monthly J Med 17:97
Bakst R, Wolden S, Yahalom J (2012) Radiation therapy for Chloroma (Granulocytic Sarcoma). Int J Radiat Oncol Biol Phys 82:1816–1822. https://doi.org/10.1016/j.ijrobp.2011.02.057
Chak LY, Sapozink MD, Cox RS (1983) Extramedullary lesions in non-lymphocytic leukemia: results of radiation therapy. Int J Radiat Oncol Biol Phys 9:1173–1176
Kawamoto K, Miyoshi H, Yoshida N et al (2016) Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients. Am J Surg Pathol 40:1473–1483. https://doi.org/10.1097/PAS.0000000000000727
Meis JM, Butler JJ, Osborne BM, Manning JT (1986) Granulocytic sarcoma in nonleukemic patients. Cancer 58:2697–2709
Cantone E, Cavaliere M, Di Lullo A et al (2016) Immunohistochemical patterns in the differential diagnosis of rhinopharyngeal granulocytic sarcoma. Oncol Lett. https://doi.org/10.3892/ol.2016.5009
Hall MD, Chen Y‑J, Schultheiss TE et al (2014) Treatment outcomes for patients with chloroma receiving radiation therapy: radiation therapy for chloroma. J Med Imaging Radiat Oncol. https://doi.org/10.1111/1754-9485.12172
Walker GV, Shihadeh F, Kantarjian H et al (2014) Comprehensive craniospinal radiation for controlling central nervous system leukemia. Int J Radiat Oncol Biol Phys 90:1119–1125. https://doi.org/10.1016/j.ijrobp.2014.08.004
Byrd JC, Edenfield WJ, Shields DJ, Dawson NA (1995) Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol 13:1800–1816. https://doi.org/10.1200/jco.1995.13.7.1800
Schlenk RF, Döhner K, Krauter J et al (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909–1918. https://doi.org/10.1056/NEJMoa074306
Döhner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424–447. https://doi.org/10.1182/blood-2016-08-733196
Dabaja B (2017) Renaissance of low-dose radiotherapy concepts for cutaneous lymphomas. Oncol Res Treat. https://doi.org/10.1159/000470845
Elsayad K, Kriz J, Moustakis C et al (2015) Total skin electron beam for primary cutaneous T‑cell lymphoma. Int J Radiat Oncol Biol Phys 93:1077–1086. https://doi.org/10.1016/j.ijrobp.2015.08.041
Elsayad K, Oertel M, Haverkamp U, Eich HT (2017) The effectiveness of radiotherapy for leukemia cutis. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-016-2338-6
Chen W‑Y, Wang C‑W, Chang C‑H et al (2013) Clinicopathologic features and responses to radiotherapy of myeloid sarcoma. Radiat Oncol 8:245. https://doi.org/10.1186/1748-717X-8-245
Bastianutto C, Mian A, Symes J et al (2007) Local radiotherapy induces homing of hematopoietic stem cells to the irradiated bone marrow. Cancer Res 67:10112–10116. https://doi.org/10.1158/0008-5472.CAN-07-2192
Collis SJ, Neutzel S, Thompson TL et al (2004) Hematopoietic progenitor stem cell homing in mice lethally irradiated with ionizing radiation at differing dose rates. Radiat Res 162:48–55
Plett PA, Frankovitz SM, Orschell-Traycoff CM (2002) In vivo trafficking, cell cycle activity, and engraftment potential of phenotypically defined primitive hematopoietic cells after transplantation into irradiated or nonirradiated recipients. Blood 100:3545–3552. https://doi.org/10.1182/blood.V100.10.3545
Sauer MG (2015) Cognitive deficits following hematopoietic stem cell transplantation in childhood. Strahlenther Onkol 191:456–457
Fleckenstein J, Kremp K, Kremp S et al (2016) IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC: a direct comparison of PET-based treatment planning. Strahlenther Onkol 192:75–82. https://doi.org/10.1007/s00066-015-0900-9
Jöst V, Kretschmer M, Sabatino M et al (2015) Heart dose reduction in breast cancer treatment with simultaneous integrated boost: comparison of treatment planning and dosimetry for a novel hybrid technique and 3D-CRT. Strahlenther Onkol 191:734–741. https://doi.org/10.1007/s00066-015-0874-7
Moon SH, Cho KH, Lee C‑G et al (2016) IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma : survival outcome in a Korean multi-institutional retrospective study (KROG 11-06). Strahlenther Onkol 192:377–385. https://doi.org/10.1007/s00066-016-0959-y
Bullinger L, Döhner K, Döhner H (2017) Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol 35:934–946. https://doi.org/10.1200/JCO.2016.71.2208
Port M, Böttcher M, Thol F et al (2014) Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol 93:1279–1286. https://doi.org/10.1007/s00277-014-2072-6
Carow CE, Levenstein M, Kaufmann SH et al (1996) Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 87:1089–1096
Rosnet O, Bühring HJ, Marchetto S et al (1996) Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10:238–248
Ansari-Lari MA, Yang C‑F, Tinawi-Aljundi R et al (2004) FLT3 mutations in myeloid sarcoma. Br J Haematol 126:785–791. https://doi.org/10.1111/j.1365-2141.2004.05124.x
Mead AJ, Linch DC, Hills RK et al (2007) FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110:1262–1270. https://doi.org/10.1182/blood-2006-04-015826
Yanada M, Matsuo K, Suzuki T et al (2005) Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 19:1345–1349. https://doi.org/10.1038/sj.leu.2403838
Cribe A‑SWI, Steenhof M, Marcher CW et al (2013) Extramedullary disease in patients with acute myeloid leukemia assessed by (18)F-FDG PET. Eur J Haematol 90:273–278. https://doi.org/10.1111/ejh.12085
Reinartz G, Haverkamp U, Wullenkord R et al (2016) 4D-Listmode-PET-CT and 4D-CT for optimizing PTV margins in gastric lymphoma: determination of intra- and interfractional gastric motion. Strahlenther Onkol 192:322–332. https://doi.org/10.1007/s00066-016-0949-0
Kai T, Kimura H, Shiga Y et al (2006) Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy. Int J Hematol 83:337–340. https://doi.org/10.1532/IJH97.05167
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
M. Oertel, K. Elsayad, U. Haverkamp, M. Stelljes and H.T. Eich declare that they have no competing interests.
Ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Additional information
M. Oertel and K. Elsayad contributed equally to this work.
Rights and permissions
About this article
Cite this article
Oertel, M., Elsayad, K., Haverkamp, U. et al. Radiotherapy for extramedullary leukaemic manifestation (Chloroma). Strahlenther Onkol 194, 164–173 (2018). https://doi.org/10.1007/s00066-017-1236-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-017-1236-4